Herausforderungen an die klinische Evaluation und Gesundheitsökonomie auf dem Weg zur personalisierten Medizin

Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation

(2013) Mark H. Eckman   ANNALS OF INTERNAL MEDICINE

What principles should govern the use of managed entry agreements?

(2011) Marianne Klemp et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE

Methodological and practical challenges for personalized cancer therapies

(2011) Ignacio I. Wistuba et al.   Nature Reviews Clinical Oncology

Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response

(2011) Hans-Georg Eichler et al.   NATURE REVIEWS DRUG DISCOVERY

Innovative tests for patient-tailored treatments: demonstrating value in the age of personalized medicine

(2011) Laura Housman   Personalized Medicine

Challenge of evidence in individualized medicine

(2011) Kathleen Kraft et al.   Personalized Medicine

Translational informatics in personalized medicine

(2011) Eric D Perakslis et al.   Personalized Medicine

Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations

(2010) Gin Gin Gan et al.   ANNALS OF HEMATOLOGY

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

(2010) Jakub Adamski et al.   BMC HEALTH SERVICES RESEARCH

Designing a Randomized Clinical Trial to Evaluate Personalized Medicine: A New Approach Based on Risk Prediction

(2010) S. G. Baker et al.   JNCI-Journal of the National Cancer Institute

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

(2010) Lars Wallentin et al.   LANCET

Personalized medicine in oncology: the future is now

(2010) Richard L. Schilsky   NATURE REVIEWS DRUG DISCOVERY

Cost Effectiveness of Pharmacogenomics

(2010) William B. Wong et al.   PHARMACOECONOMICS

Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges

(2009) Sumithra J. Mandrekar et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial

(2009) N. Mittmann et al.   JNCI-Journal of the National Cancer Institute

Next generation oncology drug development: opportunities and challenges

(2009) Martin E. Gutierrez et al.   Nature Reviews Clinical Oncology

The microeconomics of personalized medicine: today's challenge and tomorrow's promise

(2009) Jerel C. Davis et al.   NATURE REVIEWS DRUG DISCOVERY

Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes

(2009) Stefan Vegter et al.   PHARMACOECONOMICS

A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing

(2009) Lisa M. Meckley et al.   PHARMACOECONOMICS

Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement— A systematic review and meta analysis

(2009) Limei Yang et al.   THROMBOSIS RESEARCH

On the Eve of Personalized Medicine in Oncology

(2008) T. J. Yeatman et al.   CANCER RESEARCH

Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine

(2008) Xian Zhou et al.   Clinical Trials

Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin

(2008) Andrew McWilliam et al.   Personalized Medicine

A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study

(2008) Louise A. Donnelly et al.   Pharmacogenetics and Genomics